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Development of a recombinant vaccine against human onchocerciasis
David Abraham a, John Graham-Brownb, Darrick Carterc, Sean A. Grayc, Jessica A. Hessa, Benjamin L. Makepeaceb
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a
Department of Microbiology and Immunology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA; bInstitute of
Infection, Veterinary & Ecological Sciences, University of Liverpool, Liverpool, UK; cPAI Life Sciences Inc, Seattle, WA, USA; dLaboratory of Molecular
Parasitology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY, USA

ABSTRACT

Introduction: Human onchocerciasis caused by the filarial nematode parasite Onchocerca volvulus
remains a major cause of debilitating disease infecting millions primarily in Sub-Saharan Africa. The
development of a prophylactic vaccine, along with mass drug administration, would facilitate meeting
the goal of onchocerciasis elimination by 2030.
Areas covered: Models used to study immunity to Onchocerca include natural infection of cattle with
Onchocerca ochengi and O. volvulus infective third-stage larvae implanted within diffusion chambers in
mice. A vaccine, comprised of two adjuvanted recombinant antigens, induced protective immunity in
genetically diverse mice suggesting that it will function similarly in diverse human populations. These
antigens were recognized by immune humans and also induced protective immunity against Brugia
malayi. We describe the development of a fusion protein composed of the two vaccine antigens with
the plan to test the vaccine in cows and non-human primates as a prelude to the initiation of phase 1
clinical trials.
Expert opinion: The adjuvanted O. volvulus vaccine composed of two antigens Ov-103 and Ov-RAL-2
was shown to be consistently effective at inducing protective immunity using multiple immune
mechanisms. The vaccine is ready for further evaluation in other animal models before moving to
clinical trials in humans.

1. Onchocerciasis – the need for a prophylactic
vaccine
Human onchocerciasis (‘river blindness’), caused by the filarial
nematode parasite Onchocerca volvulus, is a major cause of
infectious blindness, skin disease, and chronic disability. It
infects many millions worldwide with 99% of the cases sus
tained in 31 countries of Sub-Saharan Africa- resulting in wide
spread vision impairment and blindness. Current estimates put
120 million people at risk [1,2]. The Global Burden of Disease
Study estimated in 2017 that there were 20.9 million people
infected worldwide, of which 14.6 million had skin disease and
1.15 million had vision loss [3,4] (Figure 1). Importantly, it has
become apparent in recent years that onchocerciasisassociated epilepsy (OAE) is also an important public health
problem caused by onchocerciasis. In a recent door-to-door
survey in Mvolo, an onchocerciasis endemic region in South
Sudan, the prevalence of epilepsy in this population was
higher (5.1%) than blindness (2.8%) [5].
Long the focus of efforts to alleviate morbidity and lost
productivity, onchocerciasis has been identified by the World
Health Organization as a potential candidate for global elim
ination through mass drug administration (MDA) of the
donated drug ivermectin (IVM) (Mectizan®) [6–8]. This plan
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began in the 1990’s as the ‘Onchocerciasis Elimination in the
Americas’ and later by the ‘African Programme for
Onchocerciasis Control’ (APOC) in 1995 with a World Health
Assembly goal to establish community-based sustainable
treatments of 50 million people in 19 African countries having
meso- and hyper-endemicity by 2010 [7,9]. In 2015, the mis
sion of onchocerciasis elimination for Africa was passed from
APOC to its successor, the Expanded Special Programme for
the Elimination of Neglected Tropical Diseases [10]. Addition
of vegetation ‘slash and clear’ for vector control, as
a supplement to MDA, has been proposed as an adjunct to
accelerate elimination of onchocerciasis [11]. However, numer
ous and formidable technical and logistical obstacles must still
be overcome before the ambitious goal of elimination by 2030
can be achieved in Africa [9,12]. These include (1) MDA of IVM
cannot be used in 11 Central African countries co-endemic
with Loa loa infections due to the risk of severe adverse events
[13–16]; (2) The few drugs active against the adult stage of the
parasite are not used for MDA, and IVM, as well as the recently
approved drug moxidectin, are only effective against micro
filariae [17]; (3) The practical complication of treating people
for 14 to 35 years compounds the difficulty of implementing
the plan [7,8]; (4) Experimental studies indicate that suscept
ibility to reinfection may increase after treatment, further
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Article highlights
●

●
●
●

A vaccine composed of two antigens Ov-103 and Ov-RAL-2 in com
bination with the adjuvants alum or Advax-2 was shown to consis
tently induce protective immunity to O. volvulus in mice.
The vaccine was effective at inducing protective immunity in geneti
cally diverse mice and against other filarial worms.
Trials are ongoing testing the vaccine against natural infection of
cows with O. ochengi
A fusion protein comprised of the two antigens is undergoing testing
in mice, cows and non-human primates prior to clinical trials

complicating the disruption of the transmission cycle [18–20];
and finally (5) The potential emergence of IVM-resistant
O. volvulus, may limit the long-term effectiveness of MDA
and, in time, undermine all of the gains achieved by oncho
cerciasis control programs [21–29]. Originally developed for
veterinary use, IVM was re-purposed for use as
a microfilaricidal drug in humans, initially to great effect
[30,31]. While current evidence for IVM resistance in
O. volvulus is far from definitive, it is quite clear that suboptimal responses to IVM in the treatment of river blindness
have been identified, in particular, as manifested by faster
rates of microfilarial skin repopulation linked to decreased
effects of IVM on female worm fecundity [32]. It should be
noted that IVM was first used for many years to prevent
heartworm disease caused by the filarial parasite Dirofilaria
immitis in domestic dogs and cats, but it has been demon
strated that IVM-resistant D. immitis is already circulating in
the United States [33]. Complicating the challenges with rely
ing only on MDA with IVM is that IVM is not administered to
children under 5 years old and a macrofilaricidal drug, dox
ycycline, cannot be given to children under 9 thus limiting the
indications for these two drugs. In addition, doxycycline
requires 6 weeks of treatment to be effective which further
diminishes its utility [34]. Thus, children are not only vulner
able to infection but become reservoirs for transmission [35].
The successes of the control programs must be weighed
against the fact that since 1995 only a 31% reduction in the
incidence of onchocerciasis has been achieved in Africa [2,36–
38]. In 2016, APOC called for 1.15 billion treatments until 2045,
though many neglected tropical disease experts doubt that
onchocerciasis can ever be eliminated through MDA with IVM

alone, due to the aforementioned limitations [39,40].
Moreover, due to the high cost, MDA is not currently imple
mented in areas of low prevalence in Africa. This may con
tribute to continued transmission through human migrations
that may result in reintroducing the parasite back into regions
where it had once been controlled [16].
It is clear to the public health community dedicated to the
control of this disease that additional tools are critically
needed to support the existing control measures [41–43]. It
is equally clear that an effective vaccine aimed at preventing
infection with O. volvulus infective larvae (L3) would be an
essential, additional component in the effort to control onch
ocerciasis. Moreover, it is recognized that a high burden of
OAE in onchocerciasis endemic areas with high ongoing trans
mission adds to the importance of preventing new infections
by a vaccine targeting children under 5 years old who are at
risk for developing OAE including nodding syndrome [44].
Vaccine development against infection with O. volvulus has
been the subject of much thought and work in the past
through the funding (1985–1999) from the Edna McConnell
Clark Foundation [45–49]. This approach was endorsed by
APOC that strongly encouraged the development of
a prophylactic vaccine as part of new tools needed to meet
the onchocerciasis elimination agenda [49,50]. This was further
restated in a recent report listing the new global targets for
NTDs in the WHO roadmap 2021–2030 [51]. In 2015, an inter
national consortium launched a new global initiative, known
as TOVA – The Onchocerciasis Vaccine for Africa [52]. TOVA is
primarily focused on a vaccine comprised of recombinant
protein(s) and various adjuvants as described below, with
the goal of developing a vaccine that meets the desired target
product profiles [53]. It is envisioned that the preventive
Onchocerca vaccine will be used to partially protect vulnerable
populations, children under 5 years of age who have not yet
had access to MDA with IVM, against infection with L3.
Consequently, the adult worm burden and the number of
microfilariae produced by adult female worms will be reduced,
resulting in reduced pathology and rates of transmission.
Based on mathematical modeling, with the assumption that
such a vaccine has an initial prophylactic efficacy of 50% and
a therapeutic efficacy of 90% against microfilariae, the vaccine
would have a beneficial impact in onchocerciasis–loiasis coendemic areas by markedly reducing microfilarial loads in the

Figure 1. Stages of Onchocerca volvulus and clinical presentation.
(a) Infective third-stage larvae (L3s) recovered from infected black flies (Photo credit: Sara. Lustigman, New York Blood Center). (b) O.volvulus female worm released from nodule by
collagenase digestion (Photo credit: Adrian JF Luty, French National Research Institute for Sustainable Development). (c) Subcutaneous fibrotic Nodule found on a child from Ghana
containing adult O. volvulus. (Photo credit: Peter Soboslay, PLOS Neglected Tropical Diseases: Of Mice, Cattle, and Humans: The Immunology and Treatment of River Blindness).
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young (under 20 years) age groups, which are a major reser
voir for transmission [35]. Thus, an anti-larval vaccine would
support further reduction in transmission and as a result
ensure the success of the existing MDA with IVM. At the
same time, vaccination would allow for diminished subse
quent use of drugs and forestall drug resistance.

2. Foundation Studies – immunity in humans to
O. volvulus and the development of animal models
for the study of protective immunity
The feasibility of an anti-O. volvulus larvae vaccine is sup
ported by uncovering two distinctive expressions of anti-L3
protective immunity within the O. volvulus endemic popula
tion: (1) Immunity that impedes the development of patent
infections (microfilaria positive) in the putatively immune (PI)
individuals (i.e. individuals that had no clinical manifestations
of the disease, even though they lived for at least 10 years
within regions where onchocerciasis is endemic and were
exposed to high transmission rates of infection) [54–57]; (2)
Concomitant immunity to O. volvulus L3, which develops in
the patently infected (INF) individuals with increasing age and
is independent of the immune responses that are induced by
the adult worms and microfilariae associated with patent
infection. Concomitant immunity prevents most of the newly
acquired L3 infections from developing and results in a stable
adult worm burden in the INF [18,58,59]. This immunity is not
directed against the adult or the microfilaria stages of the
parasite. Some of the mechanisms of acquired protective
immunity against O. volvulus infection in humans (reviewed
in [45,60,61]) were shown to be associated with their ability to
mount mixed Th1/Th2 responses against O. volvulus L3 and/or
molting L3 [57,59], as well as the presence of cytophilic anti
bodies that together with the cytokines produced, induce
efficient anti-L3 antibody-dependent cell mediated cytotoxi
city (ADCC) reactions against L3 [59,62–70].
Research on the biology, pathology and immunology of
O. volvulus has been limited by the host range of the infection,
consisting of only naturally infected humans and gorillas,
although chimpanzees and mangabey monkeys are partially
permissive to patency in laboratory settings [71,72]. The mean
pre-patent period in primates ranges from 12 to 23 months
that adds to the limitations of the primate hosts for use in
experimental studies [71]. In addition, after skin penetration,
the L3 of O. volvulus migrates throughout the tissues making
accurate recovery of the parasites from infected animals chal
lenging. To overcome these impediments, a system was devel
oped in which L3 were implanted subcutaneously within
diffusion chambers, which were designed to contain larvae
in vivo without restricting the infiltration of host cells into
the parasite microenvironment. This system allows recovery
of early larval stages and the analysis of the local innate and
adaptive immune responses to the infections. Diffusion cham
bers containing L3 were implanted in primates including
chimpanzees, mangabey monkeys, rhesus monkeys, and squir
rel monkeys as well as rodents – including 4 inbred strains of
rats, 6 inbred strains of mice, and gerbils. The L3 developed
into fourth-stage larvae (L4) and increased in length over the
63 days in vivo in all tested hosts except for larvae implanted
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in squirrel monkeys and in rats. Importantly, equal survival
rates were observed with fresh and cryopreserved larvae
[73]. The combination of mouse susceptibility, development
of L3 into L4, efficient recovery of parasites and the use of
cryopreserved larvae opened the door for the use of this
model to identify protective vaccine candidates and to
develop a prophylactic vaccine against the early stages of
the infection. Importantly, the protective immunity that devel
ops in humans shares many characteristics with those
described in the mouse vaccine model, as discussed
below [74].
As an alternative approach to studying O. volvulus, other
species of Onchocerca have been identified but, unlike
O. volvulus, most of these parasitize ungulates including
domestic cattle [75]. While most of these are of negligible
importance for animal health, they present a unique opportu
nity as model systems for studying human onchocerciasis,
enabling the study of natural infection and transmission as
well as protective immunity in a way that cannot otherwise be
achieved outside human clinical trials.
Onchocerca ochengi is the most notable of these, sharing
many key characteristics with O. volvulus in terms of its gen
ome, biology, lifecycle and transmission including its arthro
pod vector (Simulium damnosum s.l.), the sedentary noduleforming nature of adult females, microfilaridermia and pre
sence of the endosymbiont Wolbachia [76–78]. Indeed, these
two parasites are so similar it is hypothesized that O. volvulus
evolved either directly from O. ochengi or another common
cattle-infecting ancestor, jumping hosts in a speciation event
coinciding with the recent introduction (in an evolutionary
context) of domestic cattle to the African continent [79]. This
theory is supported by numerous phylogenetic studies show
ing the close relationship of these two sister species [80,81].
Importantly in the context of vaccine development, this rela
tionship also extends to antigenic homology [82,83].
Accordingly, a zooprophylactic effect against infection with
O. volvulus has been inferred epidemiologically in humans
that results from natural exposure to O. ochengi in coendemic regions [84].
The bovine-O. ochengi natural transmission model is there
fore a valuable tool for human onchocerciasis research allowing
the evaluation and quantification of key aspects of infection and
the lifecycle, including disease kinetics, adult worm and micro
filarial burdens, female worm fecundity and viability. It has been
also used extensively to aid investigations into basic parasite
biology, including host-parasite interactions, vector biology and
epidemiology as well as more applied clinical studies focused on
testing vaccine candidates and efficacy trials of micro- and
macrofilaricidal drugs [85–95] (Figure 2).

3. Can animals be immunized against infection with
Onchocerca spp and develop adaptive protective
immunity?
3.1. O. ochengi bovine model
Naturally acquired immunity to O. ochengi has been demon
strated in cattle to be related to a number of factors including
host heterogeneity. A small proportion of animals in endemic
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Figure 2. The bovine-Onchocerca ochengi natural transmission model offers a number of opportunities for the study vaccines against human onchocerciasis.
(a.) Natural exposure to infection and quantification of the level of challenge through bait-capture of Simulium damnosum s.l. (circled), (b.) Longitudinal observation of infection kinetics
including emergence of adult female nodules in situ (arrow) and associated clinical parameters, (c.) Quantification of microfilarial burdens through skin snips, and (d.) Assessment of adult
worm biometrics including size, viability and fecundity via nodulectomies (Photo credits: John Graham-Brown, University of Liverpool).

regions demonstrate a putative immunity (similar to observa
tions from human populations). Female cattle and older ani
mals demonstrate an increased level of immunological
protection against microfilaridermia compared to male and
younger animals, respectively [87,89,96].
Attempts to induce immunity through experimental immu
nizations have also yielded positive results. Cattle immunized
with irradiated O. ochengi L3 demonstrated an 84% reduction in
adult female worm burdens following experimental challenge
and 53% reduction in microfilarial burdens following natural
challenge compared to unvaccinated control animals [89].
Similarly, following an initial experimental ‘immunization’ with
live O. volvulus L3, cattle demonstrated an 86% reduction in
O. ochengi adult female worm burdens compared to control
animals following subsequent experimental challenge with L3
[97]. In 2009, a study evaluating the co-administration of eight
recombinant O. volvulus antigen candidates, each formulated in
Freund’s or alum adjuvants, had shown that although no sig
nificant difference in adult female worm burdens between vac
cinated and unvaccinated animals following subsequent
exposure to natural infections was found, there was
a significant reduction in the frequency of microfilaridermia
present in vaccinated versus unvaccinated control animals [95].
This reduction was associated with antigen-specific serum IgG1
(Th2-associated antibody) and IgG2 (Th1-associated antibody)
responses [98]. The presence of IgG2 isotype antibody is of
particular interest in vaccinated protected cattle, as this isotype
is commonly associated with Th1-type immune responses and
ADCC activity in cattle [99]. The outcome of this vaccine study is
highly important because only the microfilarial stage is respon
sible for transmission and disease symptoms in onchocerciasis.
Therefore, even if a vaccine is only effective against microfilariae,
it could still play a key role in elimination programs by reducing
transmission potential [35].

3.2. O. volvulus mouse model
The mouse diffusion chamber model was validated in multiple
studies as a valuable tool for the development of a vaccine
against O. volvulus. Initially, it was determined that protective
immunity directed at larvae within diffusion chambers could

develop in mice following vaccination. Statistically significant
levels of protective immunity were induced in BALB/cByJ mice
following immunization with irradiated L3 [100]. Protective
immunity induced by irradiated L3 was dependent on IL-4and IL-5, and independent of IFN-γ, suggesting that protective
immunity was based on a Th2 CD4+ T cell response [101,102].
This conclusion was confirmed by studies that demonstrated
that the mechanism of protective immunity induced by irra
diated L3 required IgE and eosinophils [103,104].

4. Identification and selection of the recombinant
O. volvulus vaccine antigens
Although irradiated L3 were shown to consistently induce sig
nificant levels of protective immunity to O. ochengi in cows and
to O. volvulus in mice, it was clear that use of L3 recovered from
infected black flies would never be a realistic source of antigen
for a vaccine to be used in human populations. To overcome this
obstacle, two basic strategies were used to identify and clone
O. volvulus target vaccine antigens [53]. The first exploited the
potential involvement of antibodies in protective immunity by
immunoscreening various O. volvulus cDNA libraries to identify
target proteins. The second strategy identified and isolated
molecules thought to be essential during the infection process.
Twelve of 26 recombinant antigens identified by the first strategy
and four of 18 identified by the second strategy were confirmed
to induce partial but statistically significant protection in the
presence of an adjuvant (alum, block copolymer, or Freund’s
complete adjuvant) or using a DNA immunization when tested
in the O. volvulus mouse model [61]. Each of these antigens was
produced and tested under unique conditions. The next step in
the development of the O. volvulus vaccine was to produce
antigens in one laboratory under standardized conditions so
that the antigens could be compared to each other for vaccine
efficacy. From the list of protective antigens, eight were selected
using stringent scoring criteria and then produced in two differ
ent expression systems, Escherichia coli and Pichia pastoris. All of
the immunizations were with alum as the adjuvant to favor a Th2
response. The recombinant antigens Ov-103 produced by E. coli
and Ov-RAL-2 produced by P. pastoris emerged as lead vaccine
candidate antigens [105]. Both proteins are localized on the
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surface and glandular esophagus of L3 as well as in the hypo
dermis and cuticle of adult worms and on the surface of micro
filariae [106]. As the protective immunity induced by the two
antigens was partial, it was hypothesized that immunizing mice
with both antigens would enhance the protective immune
response. Mice were immunized with either a fusion or coadministration of the two antigens. IgG antibody titers were
higher with the combined antigens than with individual antigens
demonstrating that they were not immunologically competitive.
This is in contrast to other combined O. volvulus vaccine antigens
that were found to compete with each other, resulting in
reduced antibody titers [107]. However, the levels of protective
immunity induced by the co-administered vaccines were not
enhanced as compared to protection in mice immunized with
the individual antigens. Importantly vaccinated mice did not
develop IgE responses to either of the antigens [105]. To deter
mine the role of antibody in the protective immune response,
AID-/- mice, which do not produce IgG, were immunized with
either Ov-103 or Ov-RAL-2 formulated with alum. In the absence
of parasite-specific IgG immunized AID-/-mice did not develop
protective immunity. Furthermore, significant levels of parasite
killing in Ov-103 and Ov-RAL-2 vaccinated mice only occurred
when cells entered the parasite microenvironment. Based on
these studies, it was concluded that protective immunity
induced by Ov-103 and Ov-RAL-2 was dependent on crosstalk
between IgG and immune cells which suggests an ADCCdependent mechanism [108].
It was next hypothesized that the efficacy of an Onchocerca
vaccine could be amplified if the type of immune responses
induced by the vaccine were expanded. To test this hypothesis,
mice were immunized with Ov-103 and Ov-RAL-2 independently
or co-administered in combination with five different adjuvants
known to induce Th1, Th2 or combined Th1/Th2 responses. The
highest levels of larval killing were achieved in mice immunized
with the two antigens each formulated with delta inulin and CpG
oligodendronucleotide (ODN)-based adjuvant AdvaxTM-2
(Advax-2) as the adjuvant [109]. This vaccine induced significant
Th2- associated IgG1 and Th1-associated IgG2a/b antibody
responses as well as combined Th2 cytokines and IFN-γ in recall
responses, indicating the induction of a mixed Th1/Th2 response.
Both IgG1 and IgG2 mouse antibodies are cytophilic and could
participate in ADCC [98]. Immunization with the co-administered
vaccines increased antibody endpoint titers, yet correlation ana
lyses comparing parasite recovery numbers and endpoint titers
did not reveal consistent significant levels of statistical correla
tion. Importantly, the two antigens appeared to act collabora
tively, boosting the antibody response to the reciprocal antigen
and suggested that Ov-103 and Ov-RAL-2 induce two unique but
synergistic protective killing mechanisms [110].

5. Validating the Ov-103 and Ov-RAL-2 Onchocerca
vaccine for advanced preclinical development
5.1. Responses in humans to the Ov-103 and Ov-RAL-2
vaccine antigens
As Ov-103 and Ov-RAL-2 were identified as effective vaccine
antigens in mice, it was important to verify that they were also
associated with protective immunity in humans. Elevated IgG1
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and IgG3 responses to Ov-103 and Ov-RAL-2 were seen in 86%
of putatively immune individuals and 95% of individuals who
have developed concomitant immunity with age. Moreover,
human monospecific anti-Ov-103 antibodies but not anti-OvRAL-2 antibodies significantly inhibited the molting of L3
in vitro by 46% in the presence of naïve human neutrophils,
while both monospecific anti-Ov-103 and anti-Ov-RAL-2 anti
bodies significantly inhibited the molting by 70–80% when
cultured in the presence of naive human monocytes.
Interestingly, inhibition of molting by Ov-103 antibodies and
monocytes was only partially dependent on contact with the
cells, while inhibition of molting with Ov-RAL-2 antibodies was
completely dependent on contact with the monocytes. These
observations further suggest that the two antigens induce
different mechanisms of protective immunity in humans [108].
The onchocerciasis vaccine is aimed at preventing the
establishment of infection in children under 5 years old [52].
Accordingly, anti-Ov-103 and Ov-RAL-2 IgE responses were
tested in 73 children of 1–5 years of age vs. 27 children aged
6–8 from a highly endemic region in Ghana. Two tests were
used, ELISA and an antigen-specific IgE ImmunoCap assay that
determines whether the antigen-specific IgE antibodies can
mediate functional responses using a basophil histamine
release assay [111,112]. None of the children under 5 had
elevated functional Ov-103 or Ov-RAL-2 antigen-specific IgE
responses, while 3/27 and 1/27 of the children 6–8 years of
age had functional Ov-103 or Ov-RAL-2 antigen-specific IgE
responses, respectively. Thus, continuous exposure to infective
larvae with native Ov-103 and/or Ov-RAL-2 proteins did not
elicit functional IgE in children under the age of 5 living in
endemic regions in Ghana (Figure 3). This observation is pro
mising and reduces the concern that these vaccine antigens
would generate pathological atopic responses in vaccinated
children (once proven to be safe in adults) as was seen with
other helminth vaccines when tested in humans [111].

5.2. The candidate vaccine antigens also protect against
other filarial worms
It is acknowledged that a significant limitation of the
O. volvulus-mouse model is that the infection was restricted
to diffusion chambers and that the length of the infection was
limited to early larval stages. To validate the potency of the
Ov-103 and Ov-RAL-2 vaccine, the efficacy of Brugia malayi
orthologous antigens were tested in a B. malayi-gerbil model,
where the full lifecycle of the parasite develops [106]. Gerbils
were vaccinated with alum-adjuvanted Bm-103 and Bm-RAL-2
either individually, co-administered, or as a fusion protein of
the two antigens. All three vaccine formulations induced pro
tective immunity measured up to 150 days post-infection. The
fusion protein or the co-administered vaccines induced more
consistent and enhanced levels of protective immunity in
gerbils to B. malayi infection with L3 as compared to levels
achieved with the individual vaccines. Notably, the vaccines
promoted reduced fecundity in female worms recovered from
gerbils vaccinated with the fusion protein or with the coadministered vaccines, similar to what was observed in calves
vaccinated with eight vaccines and exposed to fully developed
O. ochengi patent infection [95]. Finally, serum from gerbils
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Functional anti-Ov-103 (A) or Ov-RAL-2 (B) antigen-specific IgE responses were tested using antigen-specific ImmunoCap assays on sera from 73 children ages 1–5 and 27 children ages 6–8.
The responses (kUA/L) per age group are plotted. Cutoff (0.35 kUA/L) for functional positive anti-Ov-103 (A) or Ov-RAL-2 IgE responses are marked by dashed lines.

vaccinated with the individual antigens, or with both antigens
either co-administered or as a fusion protein, killed L3 in vitro
in collaboration with peritoneal exudate cells [106].
Collectively the studies with B. malayi demonstrated that the
two antigens induced protective immunity that was enhanced
by immunization with both vaccine antigens and functioned
through an antibody/cell-dependent mechanism.

5.3. Effect of host genetics on the efficacy of the
Ov-103 and Ov-RAL-2 Onchocerca vaccine in mice
Experiments in the mouse-diffusion chamber model utilized
a limited number of inbred mouse strains and it was ques
tioned whether the vaccine would be effective in other
genetic backgrounds. The ability of the vaccine to function
in a wide variety of genetic backgrounds was considered to be
critical as the vaccine is intended for use in genetically diverse
human populations. The efficacy of the O. volvulus vaccine,
composed of the two antigens Ov-103 and Ov-RAL-2 in com
bination with the adjuvant Advax-2, was tested in mice with
disparate genetic backgrounds. Collaborative Cross recombi
nant inbred strains were crossed resulting in F1 hybrid CC
Recombinant Inbred Intercross mice (CC-RIX). The resulting
CC-RIX lines have increased genetic diversity yet are still
homogenous and reproducible. The O. volvulus vaccine suc
cessfully induced protective immunity in male and female
mice in 7 of 8 CC-RIX lines and in BALB/cByJ mice, suggesting
that this vaccine can induce protective immunity across a wide
array of genetic backgrounds. Innate protective immunity was
observed in a single CC-RIX line; however, vaccination of this
line did not enhance adaptive protective immunity following
vaccination. Comprehensive analysis of effector cell recruit
ment, cytokines, chemokines and antibody responses revealed
that each line of CC-RIX mice had a different adaptive immune
response profile following vaccination and L3 challenge that
consisted of a unique combination of multiple immune fac
tors. Statistical analyses did not reveal correlations between
individual factors or groups of factors and the presence of
protective immunity. Studies in the CC-RIX mice demonstrated
that the bivalent co-administered vaccine composed of Advax-

2-adjuvanted Ov-103 and Ov-RAL-2 was effective across a wide
range of genetic backgrounds and suggests that the vaccine
can induce several different types of protective immune
mechanisms [113].

6. Clinical development of the onchocerciasis
vaccine for humans
6.1. Novel lead candidate vaccine antigen construction
Following selection of Ov-103 and Ov-RAL-2 as the lead vac
cine candidates, we combined them into a single fusion pro
tein. This is commonly done for subunit vaccines and greatly
simplifies process development, toxicology, and cGMP manu
facturing resulting in significant time- and cost-savings. Two
fusion proteins were generated and tested, Ov-Fus1 and OvFus2. The Ov-103 and Ov-RAL-2 subunits were separated by
a flexible, 12-amino-acid glycine/serine linker (GS) to promote
independent folding of each subunit. Ov-Fus1 was designed as
Ov-103-(GS)-Ov-RAL-2, whereas Ov-Fus2 was in the reverse
orientation. Both fusions were produced in both E. coli and
P. pastoris. Yeast expression was chosen due to its multiple
production advantages including scalability, absence of endo
toxin by-products, more native folding, and potential posttranslational modifications. Protection studies in mice com
pared the two fusion constructs with readouts including vac
cine-induced IgG/IgG1/IgG2 titers, cytokine production, and
killing of L3 larvae within the diffusion chambers. Ov-Fus1
(P. pastoris) emerged as the lead protective fusion protein
vaccine candidate for future clinical development. Producing
a single fusion antigen would significantly simplify manufac
turing, testing, and release of the vaccine antigen as well as
administration to humans.

6.2. Process development of Ov-Fus1
Once the lead fusion vaccine antigen was selected, we
initiated translational development of the candidate. Ov-Fus1
was designed in silico without a 6 × His affinity tag, codon
optimized for production in P. pastoris, and cloned into the
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vector pPICZα A. P. pastoris transformants were selected on
YPD agar supplemented with 100 µg/mL zeocin, and indivi
dual subclones were screened for expression and secretion of
the antigen. Lead clone (Ov-Fus1-9 H) with highest levels of
antigen production was used to construct a research cell bank
(RCB). Ov-Fus1 was initially produced by fermentation at the
5 L-scale and then using optimized conditions for up to
30 L-scale. Following fermentation, the clear supernatant was
filter sterilized, concentrated, diafiltered (20 mM Tris pH 8.0)
and the Ov-Fus1 protein purified using two ion-exchange
chromatography steps performed in tandem; a negative
pass, designed not to bind Ov-Fus1 while binding and remov
ing non-target proteins followed by a second positive pass (Q
Sepharose column) resulting in a purity of Ov-Fus1 of ~90%.
The Ov-Fus1 was then polished to >98% purity using
a hydrophobic interaction resin. Yields of Ov-Fus1 (~30 kDa)
averaged 90 mg per liter with endotoxin levels below 100 EU/
mg, which is well below the endotoxin levels allowed per
injection (0.05 EU/mg) of a vaccine, assuming the onchocer
ciasis vaccine will be tested at 50 or 100 μg per injection.
Purified Ov-Fus1 was tested for appearance, purity, sterility,
endotoxin, and concentration before a Certificate of Testing
was issued.

6.3. Vaccine trials against natural infection with
O. ochengi in Cameroon
The Adamawa Region of north Cameroon is a major cattlerearing area characterized by savanna grasslands and river
systems. Unsurprisingly due to the abundance of host species
and transmission sites, O. ochengi is endemic to this region,
making it an ideal location to study the bovine-O. ochengi
natural transmission model as well as the development of
vaccine-induced protection against natural infection with
O. ochengi [86,89,90,95,97].
Studying protective immune responses in cattle against
O. ochengi is challenging because newly exposed, naive cattle
are generally not maintained long enough to study acquired
protective immunity or concomitant immunity; however,
a few studies were able to characterize some of its aspects.
Naturally acquired infections are typically long-lived, with
most cattle continuing to acquire new infections over the
course of their lifetime similar to what is observed in humans
[4,87,89]. For instance, infected Cameroonian cattle with an
initial geometric mean nodule load of ~80 acquired an aver
age of 17 additional nodules when exposed to natural trans
mission for two additional years, whereas under 2 nodules on
average were acquired by uninfected putative immune ani
mals over the same timeframe [114]. Investigation of the
bovine immune response following experimental infection
of immunologically naïve animals with O. ochengi demon
strated that disease progression was also associated with
a reduction in lymphoproliferative, parasite-specific IgG2
and pro-inflammatory cytokine (IL-2, IL-4 and IFN-γ)
responses. Both naturally acquired and vaccine-inducedimmunity offered some evidence of the types of immune
responses required for protective immunity [95]. The hetero
geneity of these naturally acquired and vaccine induced
immune responses in cattle as well as the scarcity of bovine
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immunological reagents makes a detailed characterization of
immunity more challenging. Both Th1 and Th2 responses
appear to be required for protective immunity against
O. ochengi which is consistent with the findings from rodent
models investigating vaccine-induced immunity using Ov103, Ov-RAL-2 individually, co-administered, or as a fusion
protein [105,108].
Current investigations in cattle are presently aimed at max
imizing the potential protective effects of a co-administration
of Ov-103 and Ov-RAL-2 or a Ov-Fus1-based adjuvanted vac
cine in cattle against natural infection with O. ochengi, with
the intention of inducing antigen-specific mixed Th1 and Th2
responses. To this end, a number of adjuvant formulations
have been trialed using three distinct adjuvants, including
Rehydragel LV alum, a cattle-specific formulation of Advax-2
which induced a high degree of immunological protection in
the experimental mouse O. volvulus model, and a veterinary
water-in-oil-in-water (w/o/w) emulsion (MontanideTM ISA
206VG) which has previously been shown to induce protective
immunity in cattle against the parasitic trematode Fasciola
hepatica [110,115]. Preliminary immunogenicity studies con
sisting of a prime immunization followed by two booster
inoculations (1 month apart) have indicated that immuniza
tion with the Montanide-adjuvanted vaccine was the most
successful in inducing Th1/Th2-associated antibody
responses.
The ability to observe and measure the vaccine induced
immune responses present in cattle following immunization
and subsequent natural challenge is central to the relevance
of ongoing and future bovine vaccine trials. This not only
gives us a better understanding of which components of the
vaccine and resulting immune response are important for
immunological protection, but also a deeper appreciation of
the types of vaccine-induced immune responses to be
expected in a heterogenous host population, thereby inform
ing future human clinical trials. There are a number of wellestablished protocols for the investigation of bovine humoral
and cellular responses, as well as analytical methods to help
account for the variable nature of immune responses in phe
notypically diverse populations [116]. Additionally, recent
advances in omics-type approaches present opportunities for
in-depth immunological analysis of clinical samples and ex
vivo cell cultures, which have not previously been possible
due to the remote field location of these trials [117].
Moreover, epitope-mapping techniques can be used with
serum collected from vaccinated and putatively immune ani
mals to identify specific natural- and vaccine-induced epitopes
displaying a high degree of immunogenicity and associations
with protective immunity for further research and develop
ment [118,119].

6.4. Selection of final animal model for verification of
vaccine efficacy prior to testing in humans
While in many cases antigen selection can be performed using
appropriate models of a pathogen’s lifecycle, due to the com
plexity of the innate response triggered by adjuvants one
must consider species-specific differences in receptor path
ways – particularly when using combination adjuvants that
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trigger both inflammatory and Toll-like receptors [120,121].
Mice tend to have very potent responses to innate agonists –
perhaps due to their limited lifespan – which would make it
beneficial for them to respond strongly to invading patho
gens, as the risk of developing auto-immunity in a short
time is low [122]. For this reason, considering higher order
animal models is key to predictive modeling of an adjuvanted
immune response in humans. Domesticated animals like cows
and pigs may be a good choice as the close proximity of herds
mimic human evolution of tribal and city living and thereby
exposure to innate agonists. Notably, as outlined above, the
protective responses in humans against O. volvulus and those
in cattle against O. ochengi were shown to be similar. Despite
this, and due mostly to evolutionary similarities, non-human
primates (NHPs) are still considered among the best animal
models for selecting the best adjuvanted vaccines for humans
[123]. Other than their innate systems’ similarity, the fact that
some NHP species are natural hosts for other helminths and
therefore suffer from diseases like schistosomiasis make them
excellent models of vaccine efficacy and protection across
helminth species [124,125]. For these reasons, as part of our
current plans for the clinical development of the Ov-Fus1
vaccine for onchocerciasis, we plan to verify protection data
gathered in mice in NHPs prior to incurring the financial and
time costs of human clinical development of an imperfect
vaccine. Current design of our NHP studies includes various
‘GO/NO GO’ criteria. Among the ‘GO’ criteria would be induc
tion of neutralizing IgG titers, demonstration of ADCC killing of
L3 larvae (either in vivo or ex vivo), and induction of cytokines
indicative of a robust Th1 response. Key ‘NO GO’ criteria will
likely be failure to kill L3 larvae or reduce parasite burden or
the induction of IgE antibodies.

6.5. Clinical trial criteria
A clinical path to successful deployment of an onchocerciasis
vaccine has to take into consideration ‘need, availability and
cost’ [126]. This breaks down into numerous factors that must
be considered: The desired indication, the final target popula
tion, deployment conditions of the product, route of adminis
tration, and duration of the protective response. It is therefore
imperative to develop a target product profile prior to enter
ing clinical trials so that at the end of the human studies the
data gathered will support the targeted deployment scenario.
TOVA’s present target product profile for an onchocerciasis
vaccine in Africa assumes a > 50% efficacy at preventing
establishment of incoming infections [35]. The target popula
tion are children under 5 years of age. For these reasons, the
human clinical trials will be broken down into first testing the
safety of the vaccine in a non-endemic area, i.e. a phase 1
human trial in adults to simply demonstrate safety of the
vaccine formulation in individuals who have not been exposed
to O. volvulus. Once this is complete, the clinical trial will be
performed as a phase 1B safety study in endemic countries to
demonstrate safety and immunogenicity in adult individuals
who may have encountered the parasite in their lifetime. With
this in mind, our clinical trial plan will begin by screening
naïve patient sera for cross-reactivity to Ov-Fus1 alone or to
total O. volvulus lysates. Post-vaccinated sera will include

evaluating vaccine-specific responses, IgG titers and cytokine
induction specific to Ov-Fus1 and again compared to total
O. volvulus lysates. Future studies would include phase 2 in
adults where immunological markers of efficacy would be also
collected (e.g. larvae-specific seroconversion as well as in vitro
L3 inhibition of molting and/or killing by sera of vaccinated
individuals in the presence of effector cells), as well as con
comitant age de-escalation studies to reach the target dosing
ages. The development of biomarkers for the early diagnosis
of O. volvulus infections will be an important adjunct during
this phase [127]. Finally, a pivotal phase 3 efficacy study would
be performed in children examining prophylactic power of the
vaccine for registration of the product.

7. Expert opinion
The O. volvulus vaccine composed of two antigens Ov-103 and
Ov-RAL-2 in combination with the adjuvant alum or Advax-2
was shown to be consistently effective at inducing protective
immunity and is now the lead vaccine for clinical develop
ment. The mechanism of protective immunity induced by the
vaccine in mice was dependent on the development of an IgG
response. Likewise naturally acquired human antigen-specific
monospecific antibodies prevented molting in vitro at
a statistically significant level. B. malayi orthologues of the
two vaccine antigens also induced antibodies in gerbils that
killed larvae in vitro and significantly prevented the develop
ment of adult worms and fecundity in the developed female
worms. The vaccine is composed of two antigens inoculated
as a co-administration or as a fusion vaccine. Each antigen can
induce protective immunity independently or as a synergized
protective response when combined. Although alum is an
effective adjuvant in mice with these vaccine antigens, we
selected Advax-2 as the adjuvant for further analysis as it
induced both Th1 and Th2 responses similar to that seen in
immune humans and protected cows. The adjuvanted vac
cines elicited immune responses that proved to be essential
for the uniform success of the vaccine in genetically diverse
mice, where each protected CC-RIX line responded uniquely to
the vaccine. The absence of an IgE antibody response in
vaccinated mice and antigen-specific functional IgE responses
to each of the vaccine antigens in young children suggests
that the vaccine will be safe and effective in children.
Although killing of challenge parasites was not absolute in
the animal model systems, the vaccine still has clinical applic
ability assuming that it will result in ~50% decrease in worm
burden as it does in mice leading to decreases in disease and
transmission. It is also possible that in humans the vaccineinduced protective immune response will be more effective
because the challenge infection doses are much smaller – as
found in nature – or because the time for the adaptive
immune response to kill the new infections has been
extended beyond the limited time in mice. Even in the
absence of sterilizing immunity, any reduction in the number
of adult worms that develop and/or cause significant detri
mental effect on the fecundity of the developed female worms
will ultimately result in decreased pathology and transmission.
The current pre-clinical testing of the Onchocerca vaccine
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comprised of the two lead vaccine antigens in mice, cows, and
non-human primates will lead us within the next few years to
the clinical testing of the vaccine in humans.
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